{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:34:00Z","timestamp":1747172040792,"version":"3.40.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.022","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T01:15:17Z","timestamp":1492823717000},"page":"2949-2954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination"],"prefix":"10.1016","volume":"35","author":[{"given":"Lina","family":"P\u00e9rez-Breva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-0950","authenticated-orcid":false,"given":"Raquel","family":"Abad-Torreblanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Mart\u00ednez-Beneito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Puig-Barber\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alem\u00e1n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Morant-Talamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macrina","family":"Sastre-Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A.","family":"V\u00e1zquez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edez-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.022_b0005","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.04.022_b0010","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.022_b0015","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.04.022_b0020","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.vaccine.2014.03.010","article-title":"Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification","volume":"32","author":"Garrido-Estepa","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0025","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine","volume":"292","author":"De Wals","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.04.022_b0030","first-page":"0","article-title":"Current and future effects of varicella and herpes zoster vaccination in Germany - insights from a mathematical model in a country with universal varicella vaccination","author":"Horn","year":"2016","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2017.04.022_b0035","first-page":"11","article-title":"Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision","volume":"9","author":"Cano","year":"2004","journal-title":"Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"},{"key":"10.1016\/j.vaccine.2017.04.022_b0040","doi-asserted-by":"publisher","first-page":"20120147","DOI":"10.1098\/rstb.2012.0147","article-title":"The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?","volume":"368","author":"Maiden","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2017.04.022_b0045","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.ebiom.2015.08.017","article-title":"Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster","volume":"2","author":"van Lier","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0050","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.022_b0055","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.022_b0060","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.022_b0065","unstructured":"Consejo Interterritorial del sistema Nacional de Salud. Acuerdo n\u00b0413, 18 diciembre; 2000."},{"key":"10.1016\/j.vaccine.2017.04.022_b0070","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.022_b0075","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0080","unstructured":"Ponencia de Programa y Registro de Vacunaciones. Situaci\u00f3n actual de la enfermedad meningoc\u00f3cica en Espa\u00f1a. Modificaci\u00f3n de la pauta de vacunaci\u00f3n frente a meningococo C; 2005. Available at: http:\/\/wwwmsssigobes\/ciudadanos\/proteccionSalud\/infancia\/docs\/MenC_MARZO_2006pdf."},{"key":"10.1016\/j.vaccine.2017.04.022_b0085","unstructured":"Plan de prevenci\u00f3n integral de la meningitis en la Comunidad Valenciana. Generalitat Valenciana. Conseller\u00eda de Sanitat. Direcci\u00f3 General de Salut P\u00fablica; 1999."},{"key":"10.1016\/j.vaccine.2017.04.022_b0090","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.022_b0095","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.022_b0100","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/INF.0b013e3181d9e653","article-title":"Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.022_b0105","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction","volume":"19","author":"Ishola","year":"2012","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.04.022_b0110","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.vaccine.2017.04.022_b0115","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0120","unstructured":"Informe enfermedad meningoc\u00f3cica en la Comunidad Valenciana. Temporada epidemiol\u00f3gica 2013\u20132014. Conseller\u00eda de Sanitat. Direcci\u00f3n General de Salud P\u00fablica. Subdirecci\u00f3n General de Epidemiolog\u00eda y Vigilancia de la Salud. Servicio de Vigilancia y Control Epidemiol\u00f3gico. Fecha publicaci\u00f3n: Mayo 2015."},{"key":"10.1016\/j.vaccine.2017.04.022_b0125","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.022_b0130","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination","volume":"98","author":"de Whalley","year":"2013","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2017.04.022_b0135","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/cid\/ciu599","article-title":"Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance","volume":"59","author":"Maiden","year":"2014","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2017.04.022_b0140","unstructured":"Grupo de trabajo MenCC 2012, de la Ponencia de Programas y Registro de Vacunaciones. Revisi\u00f3n de la pauta de vacunaci\u00f3n frente a enfermedad meningoc\u00f3cica por serogrupo C. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e igualdad; 2013. Available at: http:\/\/wwwmsssigobes\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/docs\/MenCpdf."},{"key":"10.1016\/j.vaccine.2017.04.022_b0145","unstructured":"Changes to the meningococcal C conjugate (Men C) vaccine schedule 2013-2015. Public Health England. July 2014. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/336171\/MenC_information_for_healthcare_professionals_V7_.pdf."},{"key":"10.1016\/j.vaccine.2017.04.022_b0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2017.04.022_b0155","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"year":"2009","series-title":"Sistema de Informaci\u00f3n Vacunal (SIV). GeneralitatValenciana","author":"Pastor Villalba","key":"10.1016\/j.vaccine.2017.04.022_b0160"},{"key":"10.1016\/j.vaccine.2017.04.022_b0165","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.vaccine.2015.02.048","article-title":"Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study","volume":"33","author":"Breva","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0170","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1128\/CVI.00279-08","article-title":"Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era","volume":"15","author":"Trotter","year":"2008","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2017.04.022_b0175","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.vaccine.2017.04.022_b0180","doi-asserted-by":"publisher","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.04.022_b0185","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","article-title":"Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era","volume":"21","author":"Trotter","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0190","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1503\/cmaj.110506","article-title":"The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases","volume":"184","author":"Wilson","year":"2012","journal-title":"CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"key":"10.1016\/j.vaccine.2017.04.022_b0195","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.022_b0200","unstructured":"I Encuesta de seroprevalencia de la Comunidad Aut\u00f3noma del Pa\u00eds Vasco. Ed. Servicio de Publicaciones del Gobierno Vasco 2011. Available at: http:\/\/wwweuskadieus\/r332732\/es\/contenidos\/informacion\/vacunas_epidem\/es_4330\/adjuntos\/seroprevalenciapdf."},{"key":"10.1016\/j.vaccine.2017.04.022_b0205","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/INF.0000000000000541","article-title":"Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination","volume":"34","author":"Perrett","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.022_b0210","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2017.04.022_b0215","doi-asserted-by":"publisher","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.022_b0220","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1471-2334-14-280","article-title":"Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain)","volume":"14","author":"Perez-Breva","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.022_b0225","unstructured":"Garrido-Estepa M M-GM, Cano-Portero R. Enfermedad meningoc\u00f3cica en Espa\u00f1a. An\u00e1lisis de la temporada 2012\u20132013. Red Nacional de Vigilancia Epidemiol\u00f3gica. Publicado: Julio 2014."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17304863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T02:37:20Z","timestamp":1601951840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17304863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17304863"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}